# US 2012/0269782 A1 · Materials and methods for generating pluripotent stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269782 A1
- Document ID: US20120269782A1
- Status: Published application
- Kind: A1
- Application number: 13/516,530
- Filed: 2009-12-18
- Published: 2012-10-25
- Earliest claimed: 2009-12-18
- Assignees: Sino-American United (Shanghai) Biotechnology Institute Co., Ltd.; Sino-American iCELL (Shanghai) Biotechnology Co., Ltd.
- Inventors: Lihe Guo; Tianjin Liu
- Web page: https://patentgrep.com/patent/US20120269782A1

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/06: {Animal cells or tissues; Human cells or tissues (preservation of excised living parts A01N1/10)}
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0625: {Epidermal cells, skin cells; Cells of the oral mucosa}
- C12N 2500/84: from mammals
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/235: Leukemia inhibitory factor [LIF]
- C12N 2502/025: extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
- C12N 2506/09: from epidermal cells, from skin cells, from oral mucosa cells
- C12N 2506/13: from connective tissue cells, from mesenchymal cells
- C12N 2506/1307: from adult fibroblasts
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method of reprogramming a somatic cell to produce an induced pluripotent stem (iPS) cell which is capable of differentiating into somatic cells derived from ectoderm, mesoderm or endoderm. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells.

## Claims

### Claim 1

A method for obtaining an induced pluripotent stem cell comprising culturing one or more somatic cells on a feeder layer of amniotic cells for a period of time sufficient to reprogram the somatic cells into a pluripotent stem cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amniotic cells are amniotic epithelial cells, extra-embryonic mesenchymal cells, or amniotic fluid cells.

### Claim 3 (depends on 2)

The method of claim 2, wherein the amniotic epithelial cells are mammalian amniotic epithelial cells.

### Claim 4 (depends on 3)

The method of claim 3, wherein the mammalian amniotic epithelial cells are derived from a mammal selected from the group consisting of: primates, pig, dog, horse, cattle, sheep, rabbit and rodents.

### Claim 5 (depends on 4)

The method of claim 4, wherein the amniotic epithelial cells are human amniotic epithelial cells.

### Claim 6 (depends on 1)

The method of claim 1, wherein the amniotic epithelial cells have been cultured for fewer than 6 serial passages (P0-P5).

### Claim 7 (depends on 6)

The method of claim 6, wherein the amniotic epithelial cells are newly isolated P0 amniotic epithelial cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the somatic cells are mature somatic cells.

### Claim 9 (depends on 1)

The method of claim 1, wherein the somatic cells are somatic cells from an embryonic stage.

### Claim 10 (depends on 1)

The method of claim 1, wherein the somatic cells are selected from the group consisting of: adult skin fibroblast (ADSF) cells, human embryonic fibroblast (HEF) cells, mouse fibroblast (MF) cells, mouse embryonic fibroblast (MEF) cells, pig fibroblast (PF) cells, and pig embryonic fibroblast (PEF) cells.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cells are cultured in KO-DMEM medium.

### Claim 12 (depends on 11)

The method of claim 11, wherein the KO-DMEM medium comprises bFGF, human umbilical serum, newborn bovine serum, fetus bovine serum and LIF.

### Claim 13 (depends on 12)

The method of claim 12, wherein the KO-DMEM comprises 10 ng/ml bFGF, 5% human umbilical serum and 12 ng/ml LIF.

### Claim 14 (depends on 1)

An induced pluripotent stem cell obtained by the method of claim 1.

### Claim 15 (depends on 14)

A somatic cell, germ cell, tissue, or organ derived by inducing differentiation of the pluripotent stem cell of claim 14.

### Claim 16 (depends on 1)

A method for stem cell therapy comprising:
(a) providing a somatic cell from a subject;
(b) reprogramming the somatic cell into a pluripotent stem cell according to the method of claim 1; and
(c) inducing differentiation of the pluripotent stem cell.

### Claim 17 (depends on 16)

The method of claim 16, wherein inducing differentiation of the pluripotent stem cell occurs in vivo.

### Claim 18 (depends on 16)

The method of claim 16, wherein inducing differentiation of the pluripotent stem cell occurs in vitro.

### Claim 19 (depends on 18)

The method of claim 18 further comprising transplanting the differentiated cell into the subject.

### Claim 20 (depends on 16)

The method of claim 16, wherein the stem cell therapy is used for regenerative medicine, tissue engineering therapy, or animal breeding.
